Epicrispr Biotechnologies has locked in $90.0M in a Series C round, a hefty infusion for a biotech aiming to shrink gene-editing tools down to a more deliverable size. The company鈥檚 platform hinges on CasMINI, the smallest known Cas protein, which it uses to modulate gene expression directly in the body rather than engineering cells in a lab dish.
The round drew a broad syndicate, including Octagon Capital, Janus Henderson Investors, Fidelity Management & Research Company, Cormorant Asset Management, Sanofi Ventures, abrdn Inc., Angelini Ventures, and Readout Capital. That mix of crossover investors and strategic backers suggests interest beyond just early-stage biotech bets, though Epicrispr has kept specifics on its clinical timeline under wraps for now.
.png&w=3840&q=75)
